MR spectroscopic imaging of glutathione in the white and gray matter at 7 T with an application to multiple sclerosis
Introduction
Detection of glutathione (GSH) at clinical field strengths of 1.5 or 3 T has been difficult due to its low concentration (1–5 mM) in the normal brain. In a proton MR spectrum, the GSH resonance overlaps strongly with N-acetyl-aspartate (NAA), creatine, glutamate, lipids and macromolecular compounds so that even with increased frequency dispersion at 7 T, it cannot be isolated with single echo acquisitions. Studies using spectral editing schemes, such as MEGA-PRESS J-difference editing have been used for the detection of GSH at 4 T from a single voxel [1] spectrum.
The performance of spectral editing techniques improves with field strength due to increased frequency separation between metabolites allowing greater selectivity of the metabolite of interest. Recent studies using 7 T 1H MRS have reported linear gains in signal-to-noise ratio (SNR) with field strength. While the spectral linewidth, when measured in Hz increases with field strength due to T2 line broadening, there is a decrease in the ppm spectral linewidth [2]. Improved spectral resolution of the multiplet structure has been shown to enhance the quantification precision of myoinositol at 3 T relative to 1.5 T [3]. Increasing field strength also enhances the quantification of metabolites [4]. Hence, here, we develop a technique for GSH measurement at 7 T.
The motivation to develop this technique is that GSH is an indicator of oxidative status in the human brain. The antioxidant GSH (γ-glutamyl-cysteinyl glycine) is essential for detoxification of reactive oxygen species in brain cells [5]. The GSH S-transferase (GST) supergene family encodes isoenzymes such as GSH that are critical in the protection of cells against products of oxidative stress [6]. It has been shown that long-term prognosis and disability in multiple sclerosis (MS) is influenced by a genetically determined ability to remove toxic products of oxidative stress [7]. Genetic markers of GST were differentially expressed in chronic and acute plaque tissue relative to MS white matter (WM) [8]. Recent studies [9] have shown an increase in GSH is stimulated by extra-cellular glutamate indicating that GSH might also have a neuroprotective role to minimize Glutamate toxicity, which is a known mechanism of neurodegeneration. Hence, it is relevant to have a noninvasive measure of GSH that could be used as a marker for disease phenotype in MS.
In this study we report the unobstructed in vivo detection and quantification of GSH at 7 T over a two-dimensional region with proton MR spectroscopic imaging (MRSI) using a spectral editing scheme called band selective inversion with gradient dephasing (BASING) [10]. Normative estimates of GSH in WM and gray matter (GM) in normal subjects were compared to estimates of GSH in the normal-appearing WM (NAWM) and normal-appearing GM (NAGM) in a group of patients with MS.
Section snippets
Study population
Data from six normal volunteers and seven patients with MS are reported in this study. Two normal subjects were scanned twice to determine the reproducibility of the overall technique.
Study protocol
All experiments were performed on a 7 T GE Signa scanner (GE Healthcare, Waukesha) using an eight-channel phased-array (Nova Medical, Wilmington, MA, USA) receive coil. High-resolution anatomical images (512×512, 18 cm FOV, NEX=3, TE/TR=11/250 ms, 2/6-mm slice/gap) were acquired to prescribe the single spectral
Results
Fig. 1 shows the inversion profile of the spectral editing pulse that was used to selectively suppress the CH-GSH at 4.56 ppm on alternate scans and refocus the CH2-GSH resonance at 2.95 ppm. The sharp transition width of this pulse ensures that the application of this pulse has negligible affect on passband metabolites under investigation. This pulse was incorporated into the PRESS acquisition (Fig. 2) to generate the spectral editing acquisition used in this study. Fig. 3 demonstrates the
Discussion
In this study we report the unobstructed detection of GSH at 2.95 ppm that is well resolved from Creatine. Two-dimensional spectroscopic imaging allows a more accurate investigation of GSH in both the WM and GM. To our knowledge, this is the first study to report normative differences in WM and GM GSH concentrations in the human brain and also the first study to probe oxidative stress in MS using in vivo MR spectroscopy of GSH, an important biomarker for oxidative status in the human brain.
To
Conclusions
Spectral editing proton MR spectroscopic imaging technique was used to provide an unobstructed detection of GSH at 7 T over a two-dimensional region of interest. High SNR of detection of a low concentration metabolite like GSH demonstrates the sensitivity and potential of 7T MRSI. This technique was used in normal subjects to report significant elevation in GSH concentrations in the normal GM relative to WM. This finding is consistent with radionuclide experiments and demonstrates the validity
Acknowledgments
The author (R.S.) would like to thank Dr. Douglas Kelley (GE Healthcare) for helping with issues related to the 7 T system. This study was supported by the UC Industry-University Cooperative Research Program, ITL-BI004-10148, sponsored by the State of California in conjunction with GE Healthcare, National MS Society pilot grant (PP1182) and NIH/NCRR UCSF-CTSI Grant Number UL1 RR024131-01 and the UCSF Research Evaluation and Allocation Committee (REAC) grant.
References (35)
- et al.
Quantitative and qualitative changes in gene expression patterns characterize the activity of plaques in multiple sclerosis
Brain Res Mol Brain Res
(2003) - et al.
Highly effective water suppression for in-vivo
J Magn Reson
(1990) - et al.
SVD-based quantification of magnetic resonance signals
JMagn Reson
(1992) - et al.
The return of the frequency sweep: designing adiabatic pulses for contemporary NMR
J Magn Reson
(2001) - et al.
TE-averaged two- dimensional proton spectroscopic imaging of glutamate at 3 T
Neuroimage
(2006) - et al.
Oxidative damage to mitochondrial DNA and activity of mitochondrial enzymes in chronic active lesions of multiple sclerosis
J Neurol Sci
(2000) - et al.
Measurement of reduced glutathione (GSH) in human brain using LCModel analysis of difference-edited spectra
Magn Reson Med
(2003) - et al.
Signal-to-noise ratio and spectral linewidth improvements between 1.5 and 7 Tesla in proton echo-planar spectroscopic imaging
Magn Reson Med
(2006) - et al.
A comparative study of myo-inositol quantification using LCmodel at 1.5T and 3.0T with 3D 1H proton spectroscopic imaging of the human brain
MRI
(2004) - et al.
Glutathione pathways in the brain
Biol Chem
Glutathione S-transferase polymorphisms and their biological consequences
Pharmacology
Glutathione S-transferase polymorphisms in MS: their relationship to disability
Neurology
Glutamate induces release of glutathione from cultured rat astrocytes — a possible neuroprotective mechanism?
J Neurochem
Improved water and Lipid suppression for 3D PRESS CSI using RF band selective inversion with gradient dephasing (BASING)
Magn Reson Med
Imaging of the active B1 field in vivo
Magn Reson Med
Cited by (106)
Emerging methods and applications of ultra-high field MR spectroscopic imaging in the human brain
2022, Analytical BiochemistryCitation Excerpt :In this manner, signals like gamma-aminobutyric acid (GABA), glutamine separated from glutamate, or glycine separated from myo-Inositol, which are difficult to quantify at lower field strengths with MRSI, can be estimated more easily with UHF. This opens up prospects for the quantification of important new biomarkers in diseases such as cancer [6], multiple sclerosis [7], epilepsy [8], or hepatic encephalopathy [9], as well as in psychiatric disorders or neuroscience. Consequently, MRSI has significantly benefited from the ever increasing B0 of human whole-body MR scanners, which has currently reached 10.5T, with new installations targeting even higher B0s such as 11.7 T [10].
Glutamate, GABA and glutathione in adults with persistent post-concussive symptoms
2022, NeuroImage: ClinicalUltra-High-Field Imaging of the Pediatric Brain and Spinal Cord
2021, Magnetic Resonance Imaging Clinics of North America